MXPA04006181A - Polvo farmaceutico o nutraceutico micronizado, con liberacion inmediata. - Google Patents

Polvo farmaceutico o nutraceutico micronizado, con liberacion inmediata.

Info

Publication number
MXPA04006181A
MXPA04006181A MXPA04006181A MXPA04006181A MXPA04006181A MX PA04006181 A MXPA04006181 A MX PA04006181A MX PA04006181 A MXPA04006181 A MX PA04006181A MX PA04006181 A MXPA04006181 A MX PA04006181A MX PA04006181 A MXPA04006181 A MX PA04006181A
Authority
MX
Mexico
Prior art keywords
immediate release
micronized pharmaceutical
nutraceutical powder
nutraceutical
powder
Prior art date
Application number
MXPA04006181A
Other languages
English (en)
Inventor
Besse Jerome
Original Assignee
Besins Int Belgique
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Besins Int Belgique filed Critical Besins Int Belgique
Publication of MXPA04006181A publication Critical patent/MXPA04006181A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invencion se refiere a un polvo farmaceutico o nutraceutico, micronizado, con liberacion inmediata y que tiene una distribucion del tamano de grano de no mas que 100 mum, y que consiste en la combinacion de al menos una sustancia activa, al menos un agente humectante y al menos un diluyente.
MXPA04006181A 2001-12-27 2002-12-27 Polvo farmaceutico o nutraceutico micronizado, con liberacion inmediata. MXPA04006181A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0116934A FR2834212B1 (fr) 2001-12-27 2001-12-27 Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques
PCT/FR2002/004575 WO2003055464A1 (fr) 2001-12-27 2002-12-27 Poudre micronisee pharmaceutique ou nutraceutique a liberation immediate.

Publications (1)

Publication Number Publication Date
MXPA04006181A true MXPA04006181A (es) 2005-04-19

Family

ID=8871027

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04006181A MXPA04006181A (es) 2001-12-27 2002-12-27 Polvo farmaceutico o nutraceutico micronizado, con liberacion inmediata.

Country Status (14)

Country Link
US (2) US20030124191A1 (es)
EP (1) EP1458356A1 (es)
JP (1) JP2005520799A (es)
AU (1) AU2002364489A1 (es)
BR (1) BR0215380A (es)
CA (1) CA2471903A1 (es)
FR (1) FR2834212B1 (es)
HU (1) HUP0500509A3 (es)
IL (1) IL162671A0 (es)
MX (1) MXPA04006181A (es)
NO (1) NO20043172L (es)
PL (1) PL370202A1 (es)
RU (1) RU2302232C2 (es)
WO (1) WO2003055464A1 (es)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030091629A1 (en) * 1998-03-27 2003-05-15 Cima Labs Inc. Sublingual buccal effervescent
US6974590B2 (en) * 1998-03-27 2005-12-13 Cima Labs Inc. Sublingual buccal effervescent
WO2001030347A1 (en) 1999-10-29 2001-05-03 Orion Corporation Treatment or prevention of hypotension and shock
DE60024320T2 (de) 1999-12-28 2006-08-10 Ajinomoto Co., Inc. Orale zusammensetzungen für diabetes
SE521512C2 (sv) 2001-06-25 2003-11-11 Niconovum Ab Anordning för administrering av en substans till främre delen av en individs munhåla
US20040048779A1 (en) * 2002-05-06 2004-03-11 Erwin Schollmayer Use of rotigotine for treating the restless leg syndrome
US6830759B2 (en) * 2002-06-28 2004-12-14 Ajinomoto Co., Inc. Antidiabetic preparation for oral administration
WO2004056363A2 (en) 2002-12-20 2004-07-08 Niconovum Ab A physically and chemically stable nicotine-containing particulate material
WO2004073729A1 (ja) 2003-02-21 2004-09-02 Translational Research Ltd. 薬物の経鼻投与用組成物
US20050026883A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
JP2005097221A (ja) * 2003-09-26 2005-04-14 Sato Pharmaceutical Co Ltd 点鼻薬
US8987322B2 (en) * 2003-11-04 2015-03-24 Circ Pharma Research And Development Limited Pharmaceutical formulations for carrier-mediated transport statins and uses thereof
EP1547592A1 (en) * 2003-12-23 2005-06-29 Schwarz Pharma Ag Intranasal formulation of rotigotine
NZ548216A (en) * 2003-12-31 2010-02-26 Cima Labs Inc Generally linear effervescent oral fentanyl dosage form and methods of administering
US9114069B2 (en) 2004-08-25 2015-08-25 Aegis Therapeutics, Llc Antibacterial compositions for drug administration
US20140162965A1 (en) 2004-08-25 2014-06-12 Aegis Therapeutics, Inc. Compositions for oral drug administration
US9895444B2 (en) 2004-08-25 2018-02-20 Aegis Therapeutics, Llc Compositions for drug administration
US20060046962A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
CN106038572A (zh) 2004-10-20 2016-10-26 恩多研究公司 性甾体前体单独或与选择性雌激素受体调节剂联合用于预防和治疗绝经后女性的性功能障碍
US8080560B2 (en) * 2004-12-17 2011-12-20 3M Innovative Properties Company Immune response modifier formulations containing oleic acid and methods
DE102005042875A1 (de) * 2004-12-23 2006-09-21 Grünenthal GmbH Schnell freisetzende Darreichungsformen für Antibiotika
US20060281775A1 (en) * 2005-06-14 2006-12-14 Applied Pharmacy Services, Inc. Two-component pharmaceutical composition for the treatment of pain
WO2007085020A2 (en) * 2006-01-20 2007-07-26 Pear Tree Pharmaceuticals, Inc. Method of treating atrophic vaginitis
CA2646942C (en) 2006-03-16 2014-07-29 Niconovum Ab Improved snuff composition
CN101410012A (zh) * 2006-03-28 2009-04-15 杰佛林制药公司 低剂量的非甾体抗炎药和β-环糊精的制剂
WO2007112272A2 (en) * 2006-03-28 2007-10-04 Javelin Pharmaceuticals, Inc. Formulations of low dose diclofenac and beta-cyclodextrin
CA2654152A1 (en) * 2006-06-02 2007-12-13 Pear Tree Women's Health Care Method of treating atrophic vaginitis
US8226949B2 (en) 2006-06-23 2012-07-24 Aegis Therapeutics Llc Stabilizing alkylglycoside compositions and methods thereof
HUE026819T2 (en) * 2006-09-13 2016-07-28 22Nd Century Ltd Llc To increase the level of nicotine alkaloids
GB0618879D0 (en) 2006-09-26 2006-11-01 Zysis Ltd Pharmaceutical compositions
JP5415769B2 (ja) * 2006-12-26 2014-02-12 株式会社新日本科学 経鼻投与用製剤
EP1987815A1 (en) * 2007-05-04 2008-11-05 Schwarz Pharma Ag Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders
US20100172991A1 (en) * 2007-06-08 2010-07-08 Henry Joseph Horacek Extended Release Formulation and Methods of Treating Adrenergic Dysregulation
EP2155170A2 (en) 2007-06-08 2010-02-24 Addrenex Pharmaceuticals, Inc. Extended release formulation and method of treating adrenergic dysregulation
US8268806B2 (en) * 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
US20100055180A1 (en) * 2007-10-10 2010-03-04 Mallinckrodt Baker, Inc. Directly Compressible Granular Microcrystalline Cellulose Based Excipient, Manufacturing Process and Use Thereof
AU2008311289A1 (en) * 2007-10-10 2009-04-16 Avantor Performance Materials, Inc. Directly compressible high functionality granular microcrystalline cellulose based excipient, manufacturing process and use thereof
EP2231118B2 (en) * 2007-12-17 2017-05-17 KRKA, tovarna zdravil, d.d., Novo mesto Suspension comprising non-micronized ezetimibe micro-particles
US20090246273A1 (en) * 2008-03-27 2009-10-01 Al-Ghananeem Abeer M Ketorolac Sublingual Spray for the Treatment of Pain
JP5613657B2 (ja) 2008-03-28 2014-10-29 ヘイル バイオファーマ ベンチャーズ，エルエルシー ベンゾジアゼピン組成物の投与
US20100022471A1 (en) * 2008-07-23 2010-01-28 Sage Products Inc. Oral Moisturizer for Alleviating Dry Mouth
RU2457857C2 (ru) * 2008-08-05 2012-08-10 Виктор Владимирович Чалов Противовирусная и антимикробная композиция
US8440631B2 (en) 2008-12-22 2013-05-14 Aegis Therapeutics, Llc Compositions for drug administration
WO2010131486A1 (en) 2009-05-15 2010-11-18 Shin Nippon Biomedical Laboratories, Ltd. Intranasal pharmaceutical compositions with improved pharmacokinetics
US20110021588A1 (en) * 2009-05-15 2011-01-27 Recro Pharma, Inc. Sublingual dexmeditomidine compositions and methods of use thereof
MX2012007234A (es) * 2009-12-22 2012-07-30 Leo Pharma As Nanocristales de monohidrato de calciprotiol.
CA2823628A1 (en) 2011-01-05 2012-07-12 Hospira, Inc. Spray drying vancomycin
CN107737100A (zh) 2011-06-14 2018-02-27 哈尔生物药投资有限责任公司 苯二氮卓组合物的投与
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
ES2885523T3 (es) 2011-11-23 2021-12-14 Therapeuticsmd Inc Formulaciones y terapias de reposición hormonal de combinación naturales
PE20142314A1 (es) 2011-12-11 2015-01-23 Recro Pharma Inc Composiciones intranasales de dexmedetomidina y metodos de uso de ellas
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
CN104043104B (zh) 2013-03-15 2018-07-10 浙江创新生物有限公司 含盐酸万古霉素的喷雾干粉及其工业化制备方法
ES2904570T3 (es) * 2013-09-24 2022-04-05 Satsuma Pharmaceuticals Inc Formulación de DHE intranasal para el tratamiento del dolor de cabeza
US8785426B1 (en) 2013-12-13 2014-07-22 Upsher-Smith Laboratories, Inc. Testosterone gel compositions and related methods
CN104042562A (zh) * 2014-05-21 2014-09-17 丽珠医药集团股份有限公司 一种罗红霉素的新固体制剂
AU2015264003A1 (en) 2014-05-22 2016-11-17 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
KR101729236B1 (ko) * 2015-06-01 2017-04-21 (주)노터스생명과학 Tlr7 항진제를 포함하는 비만 또는 간질환 예방 및 치료용 약학 조성물
KR20170003459A (ko) * 2015-06-30 2017-01-09 한미약품 주식회사 암로디핀, 로자탄 및 로수바스타틴을 포함하는 약제학적 복합 제제
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
WO2018033792A2 (en) 2016-08-19 2018-02-22 Orasis Pharmaceuticals Ltd. Ophthalmic pharmaceutical compositions and uses relating thereto
BR112019013503A2 (pt) 2016-12-31 2020-01-07 Bioxcel Therapeutics, Inc. Uso de dexmedetomidina sublingual para o tratamento da agitação
US11744967B2 (en) 2017-09-26 2023-09-05 Shin Nippon Biomedical Laboratories, Ltd. Intranasal delivery devices
JP2021509677A (ja) 2018-01-05 2021-04-01 インペル ニューロファーマ インコーポレイテッド 精密嗅覚装置によるオランザピンの鼻孔間送達
CN114983981A (zh) 2018-06-27 2022-09-02 比奥克斯塞尔医疗股份有限公司 含右美托咪定的膜制剂及其制造方法
CN109125733A (zh) * 2018-10-30 2019-01-04 成都先手生物科技有限公司 一种治疗关节炎的组合物及其应用
EP3893877A4 (en) 2018-12-11 2022-09-14 Satsuma Pharmaceuticals, Inc. COMPOSITIONS, DEVICES AND METHODS FOR TREATMENT OR PREVENTION OF HEADACHE
MX2022000709A (es) 2019-07-19 2022-05-19 Bioxcel Therapeutics Inc Regimenes de tratamiento con dexmedetomidina no sedante.
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
CA3178769A1 (en) 2020-05-18 2021-11-25 Jonas Savmarker New pharmaceutical composition for drug delivery
AR127780A1 (es) 2021-11-25 2024-02-28 Orexo Ab Nueva composición farmacéutica que comprende adrenalina
CN115501236B (zh) * 2022-11-09 2024-01-23 复旦大学附属肿瘤医院 一种醋酸烯诺孕酮在制备降低肺部炎症性疾病的药物中的应用
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4760093A (en) * 1986-10-21 1988-07-26 American Home Products Corporation (Del.) Spray dried acetaminophen
JPH01213245A (ja) * 1988-02-20 1989-08-28 Ueno Seiyaku Oyo Kenkyusho:Kk 固体状ソルビトールの製法
DE3827362A1 (de) * 1988-08-12 1990-02-15 Basf Ag Pulvrige, hydrophile theophyllinformulierung und verfahren zur ihrer herstellung
US5073374A (en) * 1988-11-30 1991-12-17 Schering Corporation Fast dissolving buccal tablet
US5157030A (en) * 1989-08-25 1992-10-20 Alexander Galat Rapidly soluble aspirin compositions and method
DK0587744T3 (da) * 1991-05-28 2003-10-20 Mcneil Ppc Inc Tygbar sammensætning til frigørelse af et lægemiddel
FR2758459B1 (fr) * 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
AU1307399A (en) * 1997-11-06 1999-05-31 Orbon Corporation Stabilized, dry pharmaceutical compositions for drug delivery and methods of preparing same
UA72207C2 (uk) * 1998-04-07 2005-02-15 Брістол- Майєрс Сквібб Фарма Компані Фармацевтична композиція ефавіренцу з добавкою дезінтегруючих агентів у вигляді швидкорозчинних капсул або таблеток та спосіб її виготовлення
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
FR2795962B1 (fr) * 1999-07-08 2003-05-09 Prographarm Laboratoires Procede de fabrication de granules enrobes a gout masque et liberation immediate du principe actif
US6978894B2 (en) * 1999-12-20 2005-12-27 Merck & Co., Inc. Blister package for pharmaceutical treatment card

Also Published As

Publication number Publication date
EP1458356A1 (fr) 2004-09-22
US20050118272A1 (en) 2005-06-02
JP2005520799A (ja) 2005-07-14
BR0215380A (pt) 2004-12-07
FR2834212B1 (fr) 2004-07-09
FR2834212A1 (fr) 2003-07-04
RU2302232C2 (ru) 2007-07-10
HUP0500509A2 (hu) 2005-09-28
CA2471903A1 (fr) 2003-07-10
PL370202A1 (en) 2005-05-16
WO2003055464A1 (fr) 2003-07-10
NO20043172L (no) 2004-09-14
IL162671A0 (en) 2005-11-20
AU2002364489A1 (en) 2003-07-15
RU2004122919A (ru) 2005-04-10
US20030124191A1 (en) 2003-07-03
HUP0500509A3 (en) 2012-07-30

Similar Documents

Publication Publication Date Title
MXPA04006181A (es) Polvo farmaceutico o nutraceutico micronizado, con liberacion inmediata.
MXPA04004791A (es) Polvo micronizado para la formacion de peliculas que comprenden una sustancia activa.
IL159086A0 (en) 3-aryl-5-aryl- [1, 2, 4] -oxadiazole derivatives and pharmaceutical compositions containing the same
IL161587A0 (en) Pharmaceutical containing 3 (3-dimethylamino-1-ethyl-2-methyl-propyl) phenol and providing delayed release of the active ingredient
IL159022A0 (en) Hv protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
HK1036931A1 (en) Pharmaceutical compositions containing compounds with activity for the enhancement of absorption of active ingredients.
HK1046244A1 (en) Controlled release and taste masking oral pharmaceutical compositions.
HK1059040A1 (en) Preventives or remedies for psoriasis containing as the active ingredient il-6 antagonist
IL163552A (en) Conjugates of biologically active compounds, uses thereof and pharmaceutical compositions comprising the same
EP1476138A4 (en) MODIFIED RELEASE FORMULATIONS OF AT LEAST ONE TRAMADOL FORM
ZA200007299B (en) Pharmaceutical compositions and uses for androst-5-ene-3β, 17β-diol.
IL133397A0 (en) Pharmaceutical compositions for oral administration, comprising an active substance and a cyclodextrin
HUP0401638A3 (en) Thiopene-amides, thiazolesulfonamides as antineoplastic agents, and pharmaceutical composition containing the same
IL140897A0 (en) Benzocycloheptene derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
WO2006023814A3 (en) Effervescent composition including a grape-derived component
IL152204A0 (en) An oligopeptide having thrombopoietin receptor modulating activity and pharmaceutical compositions containing the same
MXPA02006603A (es) Forma de dosificacion de nucleo suave, de revestimiento fragil.
MXPA03008420A (es) Forma farmaceutica solida oralmente dispersa.
HUP0400179A3 (en) 2,5-diarylpyrazines, 2,5-diarylpyridines and 2,5-diarylpyrimidines, their use and pharmaceutical compositions containing them
WO2003035686A3 (en) Compositions of fsh with high sialylation degree and their use for the preparation of medicaments
WO2007011989A3 (en) Multiple active pharmaceutical ingredients combined in discrete inhalation particles and formulations thereof
AU5892399A (en) 1, 2, 4-triazole-3-thione compounds
HUP0303155A3 (en) 2-thio-substituted imidazole derivatives, the use thereof and pharmaceutical compositions containing them
AU2002340573A8 (en) Powdery active ingredient formulations
AU5626900A (en) The high bone mass gene of 11q13.3

Legal Events

Date Code Title Description
FA Abandonment or withdrawal